thalidomide has been researched along with Adrenal Cortex Cancer in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide was administered as tolerated with a starting dose of 50 mg and target dose of 200 mg /d." | 6.90 | Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry. ( Baudin, E; Beuschlein, F; Deutschbein, T; Fassnacht, M; Hahner, S; Heidemeier, A; Hescot, S; Körbl, D; Kroiss, M; Megerle, F; Neu, B; Quinkler, M; Ronchi, CL; Schlötelburg, W, 2019) |
| "Thalidomide was administered as tolerated with a starting dose of 50 mg and target dose of 200 mg /d." | 2.90 | Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry. ( Baudin, E; Beuschlein, F; Deutschbein, T; Fassnacht, M; Hahner, S; Heidemeier, A; Hescot, S; Körbl, D; Kroiss, M; Megerle, F; Neu, B; Quinkler, M; Ronchi, CL; Schlötelburg, W, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kroiss, M | 1 |
| Deutschbein, T | 1 |
| Schlötelburg, W | 1 |
| Ronchi, CL | 1 |
| Hescot, S | 1 |
| Körbl, D | 1 |
| Megerle, F | 1 |
| Beuschlein, F | 1 |
| Neu, B | 1 |
| Quinkler, M | 1 |
| Baudin, E | 1 |
| Hahner, S | 1 |
| Heidemeier, A | 1 |
| Fassnacht, M | 1 |
| Chacón, R | 1 |
| Tossen, G | 1 |
| Loria, FS | 1 |
| Chacón, M | 1 |
1 trial available for thalidomide and Adrenal Cortex Cancer
| Article | Year |
|---|---|
Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Disease-Free Survival; Europe; Fema | 2019 |
1 other study available for thalidomide and Adrenal Cortex Cancer
| Article | Year |
|---|---|
CASE 2. Response in a patient with metastatic adrenal cortical carcinoma with thalidomide.
Topics: Adrenal Cortex Neoplasms; Adult; Angiogenesis Inhibitors; Carcinoma; Female; Humans; Thalidomide | 2005 |